secwatch / observer
8-K filed March 12, 2026, 7:59 PM ET ticker XLO CIK 0001840233
regulatory confidence high sentiment neutral materiality 0.50

Xilio Therapeutics announces 1-for-14 reverse stock split to regain Nasdaq compliance

Xilio Therapeutics, Inc.

Machine-readable event card

schema_version
secwatch.filing_event.v1
accession
0001193125-26-103150
form_type
8-K
ticker
XLO
cik
0001840233
company_name
Xilio Therapeutics, Inc.
filed_at
2026-03-12T23:59:59+00:00
discovered_at
2026-05-14T18:02:36.483004+00:00
generated_at
2026-05-15T13:49:47.993236+00:00
sec_items
["3.03", "5.03", "9.01"]
event_type
regulatory
sentiment
neutral
materiality_score
0.5
calibrated_materiality_score
0.5
confidence
high
secwatch_canonical_url
https://secwatch.observer/filing/0001193125-26-103150
json_url
https://secwatch.observer/filing/0001193125-26-103150.json
markdown_url
https://secwatch.observer/filing/0001193125-26-103150.md
text_url
https://secwatch.observer/filing/0001193125-26-103150.txt
edgar_index_url
https://www.sec.gov/Archives/edgar/data/1840233/000119312526103150/0001193125-26-103150-index.htm
edgar_primary_document_url
https://www.sec.gov/Archives/edgar/data/1840233/000119312526103150/xlo-20260312.htm
generated_by_model
deepseek-v4-flash:cloud@v2
review_status
machine_generated
human_reviewed
false
corrected
false
correction_note
null
correction_timestamp
null
superseded_by
null

Source-grounded claims

e52caf3232930681e0ad73536264cbfa6f1dd56f

Xilio Therapeutics, Inc.: Filed a Certificate of Amendment to effect a 1-for-14 reverse stock split of common stock (effective 2026-03-13).

On March 12, 2026, Xilio Therapeutics, Inc. (the “Company”) filed a Certificate of Amendment to the Company’s Restated Certificate of Incorporation, as amended (the “Certificate of Amendment”), with the Secretary of State of the State of Delaware, which will effect, as of 5:00 p.m. Eastern Time, on March 13, 2026 (the “Effective Time”), a 1-for-14 reverse stock split (the “Reverse Stock Split”) of the issued and outstanding shares of the Company’s common stock, $0.0001 par value per share (the “Common Stock”).

SEC 8-K Item 5.03/5.05/5.06 confidence 0.9 SEC evidence

Comparable filings

SDOT

Nasdaq notifies Sadot Group of stockholders' equity deficiency; delisting risk

Sadot Group Inc. May 6, 2026, 7:59 PM ET regulatory Items 3.01, 5.03, 9.01

same fact type: governance_change same SEC item: 5.03, 9.01 same event type: regulatory

This filing

On March 12, 2026, Xilio Therapeutics, Inc. (the “Company”) filed a Certificate of Amendment to the Company’s Restated Certificate of Incorporation, as amended (the “Certificate of Amendment”), with the Secretary of State of the State of Delaware, which will effect, as of 5:00 p.m. Eastern Time, on March 13, 2026 (the “Effective Time”), a 1-for-14 reverse stock split (the “Reverse Stock Split”) of the issued and outstanding shares of the Company’s common stock, $0.0001 par value per share (the “Common Stock”).

Comparable filing

On or about May 1, 2026, the Company filed a Certificate of Amendment to Designation - After Issuance of Class or Series with the Secretary of State of the State of Nevada amending the provisions of its Articles of Incorporation regarding authorized capital stock.

Filing page SEC filing

SBEV

Splash Beverage receives NYSE delisting notice; shareholders' equity negative $15.3M

SPLASH BEVERAGE GROUP, INC. May 5, 2026, 7:59 PM ET regulatory Items 1.01, 1.02, 3.01, 3.02, 5.03, 7.01, 9.01

same fact type: governance_change same SEC item: 5.03, 9.01 same event type: regulatory

This filing

On March 12, 2026, Xilio Therapeutics, Inc. (the “Company”) filed a Certificate of Amendment to the Company’s Restated Certificate of Incorporation, as amended (the “Certificate of Amendment”), with the Secretary of State of the State of Delaware, which will effect, as of 5:00 p.m. Eastern Time, on March 13, 2026 (the “Effective Time”), a 1-for-14 reverse stock split (the “Reverse Stock Split”) of the issued and outstanding shares of the Company’s common stock, $0.0001 par value per share (the “Common Stock”).

Comparable filing

On May 4, 2026, the Company filed a Certificate of Withdrawal (the “Withdrawal of Designation”) with the Secretary of State of the State of Nevada and terminated the designation of its Series D Convertible Preferred Stock, par value $0.001 per share (the “Series D”). At the time of filing the Withdrawal of Designation, there were no shares of Series D issued and outstanding. The Withdrawal of Designation became effective upon filing.

Filing page SEC filing

IOT

Samsara Inc. reincorporates from Delaware to Nevada, effective June 1, 2026

Samsara Inc. June 1, 2026, 4:07 PM ET other_material Items 3.03, 5.03, 9.01

same fact type: governance_change same SEC item: 3.03, 5.03, 9.01 similar materiality

This filing

On March 12, 2026, Xilio Therapeutics, Inc. (the “Company”) filed a Certificate of Amendment to the Company’s Restated Certificate of Incorporation, as amended (the “Certificate of Amendment”), with the Secretary of State of the State of Delaware, which will effect, as of 5:00 p.m. Eastern Time, on March 13, 2026 (the “Effective Time”), a 1-for-14 reverse stock split (the “Reverse Stock Split”) of the issued and outstanding shares of the Company’s common stock, $0.0001 par value per share (the “Common Stock”).

Comparable filing

the reincorporation of the Company from the State of Delaware to the State of Nevada (the “Reincorporation”) became effective on June 1, 2026, at 12:02 a.m. Pacific Time

Filing page SEC filing

GIG

GigCapital7 domestication from Cayman Islands to Delaware effective May 8 after shareholder vote

GigCapital7 Corp. May 11, 2026, 7:59 PM ET other_material Items 3.03, 5.03, 9.01

same fact type: governance_change same SEC item: 3.03, 5.03, 9.01 similar materiality

This filing

On March 12, 2026, Xilio Therapeutics, Inc. (the “Company”) filed a Certificate of Amendment to the Company’s Restated Certificate of Incorporation, as amended (the “Certificate of Amendment”), with the Secretary of State of the State of Delaware, which will effect, as of 5:00 p.m. Eastern Time, on March 13, 2026 (the “Effective Time”), a 1-for-14 reverse stock split (the “Reverse Stock Split”) of the issued and outstanding shares of the Company’s common stock, $0.0001 par value per share (the “Common Stock”).

Comparable filing

On May 8, 2026, GigCapital7 effectuated the Domestication by filing (i) a voluntary declaration pursuant to Section 206(3) of the Companies Act (revised) of the Acts of the Cayman Islands, (ii) a certificate of corporate domestication with the Secretary of State of the State of Delaware (the “ DE SoS ”), and (iii) an interim certificate of incorporation with the DE SoS (the “ Domesticated GigCapital7 Charter ”). Domesticated GigCapital7 also adopted bylaws (the “ Domesticated GigCapital7 Bylaws ” and together with the Domesticated GigCapital7 Charter, the “ Domesticated GigCapital7 Governing Documents ”) in connection with the Domestication.

Filing page SEC filing

WAMFF

Alaska Silver simplifies capital structure, eliminates dual-class shares

Alaska Silver Corp. May 7, 2026, 7:59 PM ET other_material Items 3.03, 5.03, 7.01, 9.01

same fact type: governance_change same SEC item: 3.03, 5.03, 9.01 similar materiality

This filing

On March 12, 2026, Xilio Therapeutics, Inc. (the “Company”) filed a Certificate of Amendment to the Company’s Restated Certificate of Incorporation, as amended (the “Certificate of Amendment”), with the Secretary of State of the State of Delaware, which will effect, as of 5:00 p.m. Eastern Time, on March 13, 2026 (the “Effective Time”), a 1-for-14 reverse stock split (the “Reverse Stock Split”) of the issued and outstanding shares of the Company’s common stock, $0.0001 par value per share (the “Common Stock”).

Comparable filing

On May 6, 2026, the Board of Directors of Alaska Silver Corp. (the "Company"), approved an amendment (the "Amendment") to the Company's Articles of the Company to eliminate its dual-class share structure by (i) eliminating its proportionate voting share class and (ii) reidentifying its subordinate voting share class as the class of "Common Shares," no par value, of which the Company shall be authorized to issue an unlimited number of Common Shares.

Filing page SEC filing

JPM

JPMorgan issues $3B of 6.100% Fixed-Rate Reset Non-Cumulative Preferred Stock, Series PP

JPMORGAN CHASE & CO May 7, 2026, 7:59 PM ET other_material Items 3.03, 5.03, 8.01, 9.01

same fact type: governance_change same SEC item: 3.03, 5.03, 9.01 similar materiality

This filing

On March 12, 2026, Xilio Therapeutics, Inc. (the “Company”) filed a Certificate of Amendment to the Company’s Restated Certificate of Incorporation, as amended (the “Certificate of Amendment”), with the Secretary of State of the State of Delaware, which will effect, as of 5:00 p.m. Eastern Time, on March 13, 2026 (the “Effective Time”), a 1-for-14 reverse stock split (the “Reverse Stock Split”) of the issued and outstanding shares of the Company’s common stock, $0.0001 par value per share (the “Common Stock”).

Comparable filing

On May 6, 2026, the Company filed a Certificate of Designations, Powers, Preferences and Rights with the Secretary of State of the State of Delaware, establishing the rights, preferences, privileges, qualifications, restrictions and limitations relating to the Series PP Preferred Stock

Filing page SEC filing

KALA

KALA BIO announces 1-for-50 reverse stock split effective May 8, 2026

KALA BIO, Inc. May 7, 2026, 7:59 PM ET other_material Items 3.03, 5.03, 8.01, 9.01

same fact type: governance_change same SEC item: 3.03, 5.03, 9.01 similar materiality

This filing

On March 12, 2026, Xilio Therapeutics, Inc. (the “Company”) filed a Certificate of Amendment to the Company’s Restated Certificate of Incorporation, as amended (the “Certificate of Amendment”), with the Secretary of State of the State of Delaware, which will effect, as of 5:00 p.m. Eastern Time, on March 13, 2026 (the “Effective Time”), a 1-for-14 reverse stock split (the “Reverse Stock Split”) of the issued and outstanding shares of the Company’s common stock, $0.0001 par value per share (the “Common Stock”).

Comparable filing

On May 7, 2026, KALA BIO, Inc. (the “ Company ”) filed a Certificate of Amendment (the “ Certificate of Amendment ”) to the Company’s Restated Certificate of Incorporation (as amended, the “ Certificate of Incorporation ”) with the Secretary of State of Delaware to effect a 1-for-50 reverse stock split of the shares of the Company’s common stock, par value $0.001 per share (the “ Common Stock ”), either issued and outstanding or held by the Company as treasury stock, effective as of 4:05 p.m. (Delaware time) on May 8, 2026 (the “ Reverse Stock Split ”).

Filing page SEC filing

ENZN

Viskase Holdings adopts Section 382 Rights Plan to protect NOL assets; threshold at 4.9%

Viskase Holdings, Inc. May 5, 2026, 7:59 PM ET other_material Items 1.01, 3.03, 5.03, 7.01, 9.01

same fact type: governance_change same SEC item: 3.03, 5.03, 9.01 similar materiality

This filing

On March 12, 2026, Xilio Therapeutics, Inc. (the “Company”) filed a Certificate of Amendment to the Company’s Restated Certificate of Incorporation, as amended (the “Certificate of Amendment”), with the Secretary of State of the State of Delaware, which will effect, as of 5:00 p.m. Eastern Time, on March 13, 2026 (the “Effective Time”), a 1-for-14 reverse stock split (the “Reverse Stock Split”) of the issued and outstanding shares of the Company’s common stock, $0.0001 par value per share (the “Common Stock”).

Comparable filing

In connection with the adoption of the Section 382 Rights Agreement, the Board approved a Certificate of Designation of Series A-2 Junior Participating Preferred Stock of Viskase Holdings, Inc. (the “Certificate of Designation”). The Certificate of Designation was filed with the Secretary of the State of Delaware on May 5, 2026.

Filing page SEC filing

Source: SEC EDGAR
accession 0001193125-26-103150

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.